Compare MTC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTC | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.8M | 69.2M |
| IPO Year | 2018 | N/A |
| Metric | MTC | ATYR |
|---|---|---|
| Price | $4.45 | $0.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 59.1K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.64 |
| 52 Week High | $5.00 | $7.29 |
| Indicator | MTC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 57.15 |
| Support Level | $0.86 | $0.67 |
| Resistance Level | $5.00 | $1.09 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 33.00 | 55.48 |
MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.